Results: Baseline characteristics (overall mean ± SD) were similar between groups in terms of age, 67.9± 7.4 years; body mass index, 23.8 ± 3.8 kg/m 2 ; BMD L1-L4, 0.741 ± 0.100 g/cm 2 and TBS, 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6% ± 6.3 vs. +2.9% ± 3.3 and +4.3% ± 6.6 vs.+0.3% ± 4.1, respectively; p < 0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (r 2 = 0.04) with no correlation between the changes in BMD and TBS over 24 months. Conclusions:In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.KEY WORDS: osteoporosis, parathyroid hormone, teriparatide, bone mineral density, trabecular bone score, treatment, open-label study MINI ABSTRACTTreatment effects over two years of teriparatide versus ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine BMD and trabecular bone score (TBS). 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 3 Teriparatide induced larger increases in BMD and TBS compared to ibandronate suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug.

No abstract

No abstract